InvestSMART

Neurizon Therapeutics Limited (ASX:NUZ)

ALERT: Price-sensitive ASX Announcement for NUZ
Current share price for NUZ : $0.063 0 (0%)+
Announcement
Release
17 Jul 2026 9:25AM
Price at Release
$0.063
Full Release
download
Summary
Neurizon Therapeutics Limited announced the completion of enrolment in Regimen I of the HEALEY ALS Platform Trial for its lead drug candidate, NUZ-001, designed for the treatment of amyotrophic lateral sclerosis (ALS). The trial achieved the fastest site activation and enrolment in the history of the HEALEY ALS Platform Trial, completing in less than five months. This milestone enables Neurizon to anticipate topline efficacy and safety results by late Q2 CY2027, earlier than previously expected, marking a significant advancement in the late-stage clinical development of NUZ-001. Neurizon remains focused on accelerating access to ALS treatments and exploring broader neurodegenerative applications, driven by strong recruitment and the operational efficiencies of the trial's master protocol.
Key Points
  • Neurizon Therapeutics Limited has completed enrolment in Regimen I of the HEALEY ALS Platform Trial for NUZ-001, intended for ALS treatment.
  • The trial achieved the fastest site activation and enrolment completion, taking less than five months.
  • Topline efficacy and safety results are anticipated to be available by late Q2 CY2027.
  • The completion of enrolment marks a significant milestone in the clinical development program for NUZ-001.
  • Neurizon's strategy is focused on accelerating access to ALS treatments and exploring broader neurodegenerative applications.
  • The HEALEY ALS Platform Trial is a major collaborative initiative aimed at developing new treatments for ALS.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.